Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.31 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.31 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.31 |
| ▸ | NPM1 | P06748 | 1/20 | 0.30 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19960325 | 0.97 | CYP11B1 (0.32) | ALDH1A1HPGDKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL19960326 | 0.94 | CYP11B1 (0.34) | KMT2ACYP11B1CYP11B2EGLN1FTO | |
| SCHEMBL20090076 | 0.93 | HPGD (0.38) | ALDH1A1HPGDKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL19960320 | 0.93 | CYP11B1 (0.31) | CYP11B1CYP11B2 | |
| SCHEMBL20090186 | 0.91 | TOP1 (0.31) | — | |
| SCHEMBL19960340 | 0.90 | EGLN1 (0.31) | EGLN1 | |
| SCHEMBL19965924 | 0.89 | CYP11B1 (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL20090194 | 0.89 | — | — | |
| SCHEMBL20090198 | 0.88 | CYP11B1 (0.30) | CYP11B1CYP11B2 | |
| SCHEMBL19960322 | 0.88 | CYP11B1 (0.32) | ALDH1A1HPGDKDM4EKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10355225-B2 | Heterocyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2019-07-16 | — | — | US | disclosed |
| US-20180114923-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-04-26 | — | — | US | disclosed |
| US-20180114923-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180114923-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | CRY1, CRY2, PER2 | ALDH1A1 750/4885HPGD 2982/4885KDM4E 1997/4885 |
| US-10355225-B2 | Heterocyclic compound and organic light emitting element comprising same | CRY1, CRY2, PER2 | ALDH1A1 750/4885HPGD 2982/4885KDM4E 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.